MET and melanoma: Hepatocyte growth factor (HGF) secreted by fibroblasts leads to the resistance of BRAF-mutant melanoma to RAF inhibition via activation of the MAPK pathway, the PI3 K/AKT pathway, and the HGF receptor MET, while similar phenomena also appear in colorectal cancer [32–34].